hexamethylene bisacetamide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herwig, S | 1 |
| Su, Q | 1 |
| Zhang, W | 1 |
| Ma, Y | 1 |
| Tempst, P | 1 |
1 other study available for hexamethylene bisacetamide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Distinct temporal patterns of defensin mRNA regulation during drug-induced differentiation of human myeloid leukemia cells.
Topics: Acetamides; Biomarkers; Blood Proteins; Cell Differentiation; Cycloheximide; Cytokines; Dactinomycin | 1996 |